Whole-inactivated and virus-like particle vaccine strategies for chikungunya virus

Journal of Infectious Diseases

Volumn 214, Issue , 2016, Pages S497-S499

  DeZure, Adam D ^a   Berkowitz, Nina M ^a   Graham, Barney S ^a   Ledgerwood, Julie E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Alphavirus; Chikungunya virus; Vaccine; Virus like particle vaccine; Whole inactivated vaccine

Indexed keywords

INACTIVATED VIRUS VACCINE; VIRUS LIKE PARTICLE VACCINE; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

CHIKUNGUNYA; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; PUBLIC HEALTH PROBLEM; TRAVEL; VIRUS LIKE AGENT; VIRUS MORPHOLOGY; AFRICA; ANIMAL; ASIA; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; EUROPE; IMMUNOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); VIROLOGY; WESTERN HEMISPHERE;

AFRICA; AMERICAS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ASIA; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; EUROPE; HUMANS; VACCINES, INACTIVATED; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

EID: 85015860211     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw352     Document Type: Conference Paper

References (38)

1. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquitoborne disease. N Engl J Med 2015; 372:1231-9.
2. Eckels KH, Harrison VR, Hetrick FM. Chikungunya virus vaccine prepared by Tween-ether extraction. Appl Microbiol 1970; 19:321-5.
3. Harrison VR, Binn LN, Randall R. Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues. Am J Trop Med Hyg 1967; 16:786-91.
4. Harrison VR, Eckels KH, Bartelloni PJ, Hampton C. Production and evaluation of a formalin-killed chikungunya vaccine. J Immunol 1971; 107:643-7.
5. White A, Berman S, Lowenthal JP. Comparative immunogenicities of chikungunya vaccines propagated in monkey kidney monolayers and chick embryo suspension cultures. Appl Microbiol 1972; 23:951-2.
6. Morrison TE. Reemergence of chikungunya virus. J Virol 2014; 88:11644-7.
7. Powers AM, Logue CH. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol 2007; 88:2363-77.
8. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007; 3:e201.
9. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000; 62:681-5.
10. Plante K, Wang E, Partidos CD, et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog 2011; 7:e1002142.
11. Garcia-Arriaza J, Cepeda V, Hallengard D, et al. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol 2014; 88:3527-47.
12. Brandler S, Ruffie C, Combredet C, et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 2013; 31:3718-25.
13. Wang D, Suhrbier A, Penn-Nicholson A, et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 2011; 29:2803-9.
14. Ramsauer K, Schwameis M, Firbas C, et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 2015; 15:519-27.
15. Wang E, Volkova E, Adams AP, et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008; 26:5030-9.
16. Roy CJ, Adams AP,Wang E, et al. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis 2014; 209:1891-9.
17. Muthumani K, Lankaraman KM, Laddy DJ, et al. Immunogenicity of novel consensus-based DNA vaccines against chikungunya virus. Vaccine 2008; 26:5128-34.
18. Hallengard D, Lum FM, Kummerer BM, et al. Prime-boost immunization strategies against chikungunya virus. J Virol 2014; 88:13333-43.
19. Mallilankaraman K, Shedlock DJ, Bao H, et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011; 5:e928.
20. Zepp F. Principles of vaccine design-lessons from nature. Vaccine 2010; 28(suppl 3): C14-24.
21. Sanders B, Koldijk M, Schuitemaker H. Vaccine analysis: strategies, principles, and control. Berlin, Heidelberg: Springer-Verlag, 2015; 45-80.
22. Wressnigg N, van der Velden MV, Portsmouth D, et al. An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial. Clin Vaccine Immunol 2015; 22:267-73.
23. Kumar M, Sudeep AB, Arankalle VA. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 2012; 30:6142-9.
24. Sharma A, Gupta P, Maheshwari RK. Inactivation of chikungunya virus by 1,5 iodonapthyl azide. Virol J 2012; 9:301.
25. Gardner J, Anraku I, Le TT, et al. Chikungunya virus arthritis in adult wild-type mice. J Virol 2010; 84:8021-32.
26. Nakao E, Hotta S. Immunogenicity of purified, inactivated chikungunya virus in monkeys. Bull World Health Organ 1973; 48:559-62.
27. Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PV. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of chikungunya virus. Vaccine 2009; 27:2513-22.
28. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012; 31:58-83.
29. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006; 40:60-5.
30. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines 2010; 9:1149-76.
31. AkahataW, Yang ZY, Andersen H, et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat Med 2010; 16:334-8.
32. Metz SW, Gardner J, Geertsema C, et al. Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 2013; 7:e2124.
33. Chang LJ, Dowd KA, Mendoza FH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 2014; 384:2046-52.
34. Pal P, Dowd KA, Brien JD, et al. Development of a highly protective combination monoclonal antibody therapy against chikungunya virus. PLoS Pathog 2013; 9: e1003312.
35. Kam YW, Lee WW, Simarmata D, et al. Longitudinal analysis of the human antibody response to chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol 2012; 86:13005-15.
36. Kam YW, Simarmata D, Chow A, et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and longterm clinical protection. J Infect Dis 2012; 205:1147-54.
37. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386:857-66.
38. Yoon IK, Alera MT, Lago CB, et al. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl Trop Dis 2015; 9:e0003764.